Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.

@article{Thompson2012AntiretroviralTO,
  title={Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.},
  author={Melanie Ann Thompson and Judith A. Aberg and Jennifer F Hoy and Amalio Telenti and Constance A Benson and Pedro E. Cahn and Joseph J. Eron and Huldrych F. G{\"u}nthard and Scott M. Hammer and Peter Reiss and Douglas D. Richman and Giuliano Rizzardini and David L. Thomas and Donna M. Jacobsen and Paul A. Volberding},
  journal={JAMA},
  year={2012},
  volume={308 4},
  pages={
          387-402
        }
}
CONTEXT New trial data and drug regimens that have become available in the last 2 years warrant an update to guidelines for antiretroviral therapy (ART) in human immunodeficiency virus (HIV)-infected adults in resource-rich settings. OBJECTIVE To provide current recommendations for the treatment of adult HIV infection with ART and use of laboratory-monitoring tools. Guidelines include when to start therapy and with what drugs, monitoring for response and toxic effects, special considerations… 
View on PubMed
hiv.ch
695 Citations
Highly Influential Citations
25
Background Citations
274
Methods Citations
43
Results Citations
14

Tables from this paper

695 Citations

Citation Type

Citation Type

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel.
TLDR
This report provides guidelines for when to initiate antiretroviral therapy, selection of appropriate initial regimens, patient monitoring, when to change therapy, and what regimens to use when changing.
Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel.
IMPORTANCE New data and antiretroviral regimens expand treatment choices in resource-rich settings and warrant an update of recommendations to treat adults infected with human immunodeficiency virus…
Antiretroviral therapy in early HIV infection.
TLDR
The timing of ART in relation to primary HIV infection is addressed and compelling support for early treatment on the basis of CD4+ T-cell restoration in peripheral blood is provided.
HIV prevention in clinical care settings: 2014 recommendations of the International Antiviral Society-USA Panel.
TLDR
Data support the integration of biomedical and behavioral approaches for prevention of HIV infection in clinical care settings and a concerted effort to implement combination strategies for HIV prevention is needed to realize the goal of an AIDS-free generation.
Universal antiretroviral therapy for HIV infection: should US treatment guidelines be applied to resource-limited settings?
  • J. Gallant, S. Mehta, J. Sugarman
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2013
TLDR
It is argued that the risk-benefit considerations for initiating ART are not the same worldwide due to limitations in the ART regimens used, laboratory monitoring, and consistent availability of ART, which raises ethical questions about universally applying US guidelines in resource-limited settings at the present time.
Antiretroviral therapy for prevention of HIV transmission: implications for Europe.
TLDR
There remains a lack of strong evidence of clinical benefit for HIV-positive individuals starting ART with CD4 count above 350 cells/mm3, and a main goal of ART provision should be to increase ART coverage for all those in need.
How have guidelines on when to start antiretroviral therapy affected survival of people living with HIV infection?
TLDR
Unless HIV testing rates and ART coverage are increased globally, raising the threshold for initiation of ART in clinical guidelines may be of limited benefit in reducing mortality in HIV.
When to start antiretroviral therapy: the need for an evidence base during early HIV infection
TLDR
There is currently no evidence from randomized controlled trials to suggest that a strategy of initiating ART when the CD4 count is above 350 cells/μl results in benefit to the HIV+ person and data from observational studies are inconsistent.
CROI 2013: Advances in antiretroviral therapy.
TLDR
Encouraging results from expanded prevention of mother-to-child transmission programs, including option B+, were presented, and prevalence of transmitted (primary) drug resistance appears to be increasing in the United States, and new detection techniques may increase access to resistance testing in RLSs.
Optimal strategies for monitoring response to antiretroviral therapy in HIV-infected adults, adolescents, children and pregnant women: a systematic review
TLDR
CM’+ IM was shown to be beneficial in terms of a combined mortality and morbidity endpoint compared to CM alone, and these data support the recommendation in the 2013 WHO ART guidelines for the use of VM to confirm and diagnose ART failure, and for theUse of IM when VM is not available.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 180 REFERENCES
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel.
TLDR
Accumulating data from clinical and pathogenesis studies continue to support early institution of potent antiretroviral therapy in patients with HIV infection, and increased complexity in HIV management requires ongoing monitoring of new data for optimal treatment of HIV infection.
Antiretroviral therapy for HIV infection in 1996 : Recommendations of an international panel
TLDR
Recent data on HIV pathogenesis, methods to determine plasma HIV RNA, clinical trial data, and availability of new drugs point to the need for new approaches to treatment, and therapeutic approaches need to be updated as new data continue to emerge.
A Comparison of Initial Antiretroviral Therapy in the Swiss HIV Cohort Study and the Recommendations of the International AIDS Society-USA
TLDR
Patients receiving violation ART regimens were less likely to have an undetectable viral load after one year, which strengthens the validity of these recommendations.
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel.
TLDR
New data have provided a stronger rationale for earlier initiation of more aggressive therapy than previously recommended and reinforce the importance of careful selection of initial drug regimen for each patient for optimal long-term clinical benefit and adherence.
When to Initiate Combined Antiretroviral Therapy to Reduce Mortality and AIDS-Defining Illness in HIV-Infected Persons in Developed Countries
TLDR
Initiation of cART at a threshold CD4 count of 0.500 × 10(9) cells/L increases AIDS-free survival, and mortality did not vary substantially with the use of CD4 thresholds between 0.300 and 0.200, while Residual confounding may exist.
Timing of antiretroviral therapy for HIV-1 infection and tuberculosis.
TLDR
In persons with CD4+ T-cell counts of less than 50 per cubic millimeter, earlier ART was associated with a lower rate of new AIDS-defining illnesses and death, as compared with later ART.
European guidelines on the clinical management of HIV-1 tropism testing.
Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis.
TLDR
Starting antiretroviral therapy 2 weeks after the start of tuberculosis treatment significantly improved survival among HIV-infected adults with CD4+ T-cell counts of 200 per cubic millimeter or lower.
Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis.
  • M. Török, N. T. Yen, J. Farrar
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2011
TLDR
There were significantly more grade 4 adverse events in the immediate ART arm, supporting delayed initiation of ART in HIV-associated tuberculous meningitis.
Integration of antiretroviral therapy with tuberculosis treatment.
TLDR
Deferral of the initiation of ART to the first 4 weeks of the continuation phase of tuberculosis therapy in those with higher CD4+ T-cell counts reduced the risks of IRIS and other adverse events related to ART without increasing the risk of AIDS or death.
...
1
2
3
4
5
...